文献速递细菌感染、耐药与抗菌药物

抗生素对骨细胞内金黄色葡萄球菌的体外活性:文献叙述性综述

In vitro antibiotic activity against intraosteoblastic Staphylococcus aureus: a narrative review of the literature.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

本文综述了抗金黄色葡萄球菌药物对骨细胞内储存库的体外药效学。

要点

  • 利福霉素类和氟喹诺酮类是体外清除骨细胞内金黄色葡萄球菌最有效的两类药物。
  • 骨细胞内储存库可保护金黄色葡萄球菌免受免疫系统和多数抗生素作用。
  • 临床选择抗菌策略时尚未考虑药物对骨细胞内储存库的活性。

核心结论

  • 利福霉素类和氟喹诺酮类是体外清除骨细胞内金黄色葡萄球菌最有效的两类抗菌药物。
  • 该结果与临床数据显示的联合治疗在金黄色葡萄球菌骨科器械相关感染中的优越性一致。

主要发现

  • 利福霉素类和氟喹诺酮类在体外模型中清除骨细胞内金黄色葡萄球菌的活性最强。
  • 各研究在孵育时间、感染复数、细菌菌株和感染细胞系类型上存在差异。

临床怎么用

  • 治疗骨与关节感染时,除标准药敏、骨穿透性和抗生物膜活性外,可考虑药物对骨细胞内储存库的活性。
  • 利福霉素类联合氟喹诺酮类方案在体外对骨细胞内金黄色葡萄球菌有效,且与临床优越性数据一致。

局限性

  • 纳入研究均为体外成骨细胞感染模型,非体内研究。
  • 各研究在孵育时间、感染复数、细菌菌株和细胞系类型上存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Staphylococcus aureus - a major aetiological agent of bone and joint infection (BJI) - is associated with a high risk of relapse and chronicity, in part due to its ability to invade and persist in non-professional phagocytic bone cells such as osteoblasts. This intracellular reservoir protects S. aureus from the action of the immune system and most antibiotics. To date, the choice of antimicrobial strategies for BJI treatment mostly relies on standard susceptibility testing, bone penetration of antibiotics and their 'antibiofilm' activity. Despite the role of intracellular persistent S. aureus in the development of chronic infection, the ability of antibiotics to target the S. aureus intraosteoblastic reservoir is not considered in therapeutic choices but might represent a key determinant of treatment outcome. This review provides an overview of the intracellular pharmacokinetics of antistaphylococcal drugs used in the treatment of BJI and of their ability to target intraosteoblastic S. aureus. Thirteen studies focusing on the intraosteoblastic activity of antibiotics against S. aureus were reviewed, all relying on in vitro models of osteoblast infection. Despite varying incubation times, multiplicities of infection, bacterial strains, and the types of infected cell lines, rifamycins and fluoroquinolones remain the two most potent antimicrobial classes for intraosteoblastic S. aureus eradication, consistent with clinical data showing a superiority of this combination therapy in S. aureus orthopaedic device-related infections.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Marro FC, Abad L, Blocker AJ, et al. In vitro antibiotic activity against intraosteoblastic Staphylococcus aureus: a narrative review of the literature. J Antimicrob Chemother. 2021. PMID: 34459881. doi:10.1093/jac/dkab301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。